Quick answer
The Orthofix spinal stim 5212 is commonly searched as a model reference for the Orthofix SpinalStim bone growth therapy device. It is a noninvasive, prescription-only pulsed electromagnetic field, or PEMF, stimulator used as an adjunct after spinal fusion surgery and, under labeled conditions, as a nonoperative treatment option for failed spinal fusion when enough time has passed since the prior surgery.
It is not a spinal cord stimulator for pain control. It is also not a substitute for fusion surgery, bone grafting, fixation, imaging follow-up, or the surgeon’s postoperative plan. The most useful way to evaluate it is to look at four areas: labeled indication, daily use requirements, evidence behind PEMF-assisted fusion, and patient-specific safety limits.
For broader device context, see our spinal devices section.
What the Orthofix spinal stim 5212 is
SpinalStim is an external bone growth stimulator. Public Orthofix labeling describes it as a wearable unit that generates a low-energy pulsed electromagnetic field. Treatment coils are positioned around the fusion site so the PEMF signal can be delivered through clothing and skin to the target area. The unit includes a control module, treatment coils, an LCD, audible indicators, and a rechargeable battery.
The search phrase Orthofix spinal stim 5212 usually points to Model 5212 or closely related 5212 catalog references. AccessGUDID device identification records list Spinal Stim version or model 5212 under Orthofix US LLC as a patient-worn bone growth electromagnetic stimulator. In practice, patients may see the number on a device label, shipping record, manual, billing document, or accessory listing.
The main distinction is clinical purpose. The 5212 is a bone-healing adjunct, not a neuromodulation implant. A spinal cord stimulator is intended to alter pain signaling and commonly involves implanted leads or a trial procedure. SpinalStim is worn externally and is intended to support osteogenesis around a fusion site. Confusing the two can create unrealistic expectations, especially if a patient expects immediate pain relief from a device whose endpoint is fusion biology rather than nerve stimulation.
Indications and regulatory context
Orthofix patient labeling and FDA PMA records describe Spinal-Stim as indicated as a spinal fusion adjunct to increase the probability of fusion success and as a nonoperative treatment for salvage of failed spinal fusion, where a minimum of nine months has elapsed since the last surgery. That indication matters because it limits the claim: the device is intended to support fusion, not to treat every type of back pain, disc degeneration, radiculopathy, or hardware-related symptom.
Regulatory status should also be read carefully. FDA records show Spinal-Stim under historical PMA documentation, including a 2011 PMA supplement for design and labeling modifications. A later FDA final order published on April 16, 2026, reclassified the broader device category of non-invasive bone growth stimulators from class III to class II with special controls, effective May 18, 2026. That category-level change does not mean patients can self-prescribe the device. The current federal framework still identifies non-invasive bone growth stimulators as prescription devices, and use should follow the physician’s order and the current instructions for use.
This timeline also explains why older, and even some recently issued, product documents may not align perfectly with the latest classification language. Orthofix’s March 2025 U.S. patient manual described the device as a Class III prescription device. After the May 2026 reclassification, clinicians, billing teams, and researchers should check the most current FDA device records and labeling rather than relying on a single older manual page.
How daily treatment works
Public Orthofix instructions make daily wear central to SpinalStim therapy. The patient places the device so the treatment coils are centered around the fusion site. The device can be worn over clothing or bracing, and direct skin contact is not required. The manual states that the device should be worn each day for the number of hours prescribed by the physician, with a minimum of two hours per day.
The LCD countdown and compliance features are more than convenience functions. They support adherence tracking, which matters because the original premarket evidence separated consistent users from inconsistent users. Orthofix labeling defines inconsistent use as less than an average of two hours per day and reports that inconsistent users had success rates similar to the placebo group in the premarketing cohort. For patients, missed or shortened sessions are not a minor detail; they may reduce the potential benefit of therapy.
Daily operation is designed for home use, but it still has clear boundaries:
- The treatment clock begins after the device is turned on and at least one minute of treatment is completed.
- The LCD shows remaining treatment time and battery status.
- The device logs use for compliance monitoring.
- The battery should be charged before first use and after completing treatment.
- The device should not be worn while charging, because it does not deliver treatment during charging.
- The device has a defined treatment availability period, commonly described as up to 365 days of daily treatments.
The manual allows treatment during activities such as sitting, walking, reclining, or sleeping. Activity level, however, still depends on the surgeon’s postoperative instructions. Wearing the stimulator does not authorize bending, lifting, twisting, smoking, stopping a brace, or accelerating rehabilitation outside the surgical plan.
Evidence behind PEMF use in lumbar fusion
The evidence base for PEMF bone growth stimulation includes older randomized evidence, open-label failed-fusion data, and newer postmarket studies. It supports use in selected settings, but it should not be read as a guarantee of fusion.
Orthofix labeling summarizes an adjunct clinical trial involving 54 surgeons at 31 centers. In the randomized, double-masked phase, patients using active devices consistently, defined as an average of at least two hours per day, developed solid fusion at one year in 92.2% of cases. The placebo group developed solid fusion in 67.9% of cases. The same labeling also reports that, in a failed fusion open trial, 67% of patients with established pseudarthrosis reached successful fusion with consistent PEMF treatment without concomitant regrafting.
Those figures are often cited in discussions of SpinalStim, but they need context. The one-year fusion endpoint does not mean every patient remains fused long term, and Orthofix labeling reports lower four-year success percentages in long-term follow-up. The failed-fusion study was open-label, not a randomized blinded comparison. Surgical technique, graft material, patient selection, smoking status, diabetes control, osteoporosis, nutrition, and mechanical stability all influence fusion biology. See also: Implants.
A more recent peer-reviewed study in the Journal of Spine Surgery, published online in January 2026, evaluated PEMF after lumbar spinal surgery in patients with risk factors for nonunion. The study compared 142 PEMF-treated subjects with 47 controls at 12 months and reported successful fusion in 88.0% of treated subjects versus 68.1% of controls. Reported risk factors included prior failed fusion, multilevel fusion, nicotine use, osteoporosis, advanced age, body mass index over 30 kg/m², and diabetes. The study adds useful modern data, but it used a retrospective control arm, so it should not be treated as equivalent to a new large randomized trial.
| Evidence point | What it suggests | Key limitation |
|---|---|---|
| Original adjunct trial summarized in labeling | Consistent active-device users had higher one-year fusion rates than placebo users. | Older evidence base; long-term follow-up shows lower absolute success rates. |
| Failed-fusion open trial summarized in labeling | PEMF may be considered in selected established pseudarthrosis cases. | Open trial design and patient selection limit certainty. |
| 2026 Journal of Spine Surgery controlled evaluation | PEMF-treated high-risk lumbar fusion patients had higher 12-month fusion rates than controls. | Control arm was retrospective, not a simultaneous randomized placebo arm. |
Safety limitations and practical checks
SpinalStim is noninvasive, but that does not mean it is risk-free or suitable for every patient. The most important labeled contraindication is an implanted cardiac pacemaker, because pacemakers may be adversely affected by exposure to PEMF. Public labeling also states that safety in pregnancy and nursing has not been established, and that safety and effectiveness have not been established in people lacking skeletal maturity.
Orthofix labeling lists additional precautions. The device has not been evaluated in certain conditions, including osseous or ligamentous spinal trauma, spondylitis, Paget’s disease, moderate to severe osteoporosis, metastatic cancer, renal disease, and uncontrolled diabetes mellitus. Some of these conditions may also be relevant to whether a fusion is high risk, which is why the decision should be individualized by the treating clinician rather than generalized from online device descriptions.
Device handling matters as well. The manual instructs users not to modify, open, or disassemble the device, and states that there are no user-serviceable parts. It advises inspection before use, keeping the device dry, avoiding solvents or alcohol-based cleaning liquids, and not sterilizing the unit. It also warns that the device should not be used or charged if it appears damaged, displays an error, or stops working.
Patients with implanted electronic medical devices other than pacemakers should not assume compatibility. Orthofix labeling says the device has not been evaluated with regard to use with specific implantable electronic medical devices and advises physician consultation before use. The manual also discusses electromagnetic compatibility and notes that wireless communication equipment can affect the device if used too close to it.
Questions to ask before using SpinalStim 5212
A useful discussion with the prescribing surgeon should focus on indication, risk profile, adherence, and follow-up imaging. Patients and caregivers can ask:
- Is the device being prescribed as a routine adjunct after fusion, or because I have specific risk factors for pseudarthrosis?
- Which levels are being targeted, and how should the coils be positioned around my surgical site?
- How many hours per day should I use it, and for how many months?
- What should I do if I miss a session or cannot tolerate the full daily wear time?
- How will fusion be assessed: X-ray, flexion-extension views, CT, symptoms, or a combination?
- Do I have any implanted cardiac or electronic devices that could affect safety?
- What should I do if the display shows an error code or if the device no longer holds a charge?
For clinicians and industry readers, the 5212 also reflects a broader issue in spinal fusion support technologies. Noninvasive adjuncts are increasingly evaluated not only by device physics, but also by patient selection, adherence tracking, radiographic endpoints, and payer criteria. Documentation is therefore part of the treatment pathway. If daily use, risk factors, and imaging follow-up are not recorded clearly, it becomes harder to judge whether PEMF contributed to a fusion outcome.
Frequently asked questions
Is Orthofix SpinalStim 5212 the same as a spinal cord stimulator?
No. SpinalStim is an external bone growth stimulator that uses PEMF technology to support spinal fusion biology. A spinal cord stimulator is a neuromodulation device used for selected pain conditions and commonly involves implanted or trial leads. The purposes, mechanisms, and clinical pathways are different.
How long is the device worn each day?
Orthofix patient labeling states that SpinalStim should be worn for the number of hours prescribed by the physician, with a minimum of two hours per day. Some studies of SpinalStim also used two hours per day over a six-month treatment period, but the actual prescription should come from the treating surgeon.
Can the device be used over clothing or a brace?
Yes. Public instructions state that the device can be worn over clothing and bracing, and that direct contact with the body is not required. Proper coil positioning around the fusion site is still important, so fitting instructions from the care team should be followed.
Does SpinalStim guarantee a successful fusion?
No. Clinical data support PEMF as an adjunct in selected settings, but fusion depends on many factors, including surgical stability, graft environment, patient biology, smoking exposure, comorbidities, nutrition, medication use, and adherence to postoperative restrictions. The device should be viewed as one part of a broader fusion plan.
Who should not use the device?
Public labeling contraindicates use in individuals with an implanted cardiac pacemaker. It also says safety has not been established for pregnancy, nursing, or individuals lacking skeletal maturity, and it lists several conditions in which the device has not been evaluated. Any patient with an implanted electronic medical device or complex medical history should confirm suitability with the prescribing physician.